Pertuzumab (Perjeta®)
Drug class: HER2-directed monoclonal antibody
Mechanism of Action
Pertuzumab is a recombinant humanized monoclonal antibody that binds to the dimerization subdomain II of the human epidermal growth factor receptor 2 (HER2). It inhibits HER2 from forming heterodimers with other HER family receptors, particularly HER3, thereby blocking ligand-dependent signaling pathways involved in tumor cell proliferation and survival. Pertuzumab also mediates antibody-dependent cellular cytotoxicity. Its mechanism is complementary to Trastuzumab, which binds a different region of HER2 (1).
Approved Indications
HER2-positive metastatic breast cancer (MBC) (1)
HER2-positive early breast cancer (EBC) (1)
HER2-positive early breast cancer at high risk of recurrence (1)
Dosage and Administration
Loading dose: 840 mg IV, followed by 420 mg IV every 3 weeks (1)
Administer with Trastuzumab and chemotherapy every 3 weeks (1)
Neoadjuvant: 3–6 cycles (1)
Adjuvant: Up to 18 cycles (1 year) (1)
MBC: Continue every 3 weeks with the recommended combination regimen (1)
Key clinical benefits
Improves progression-free survival (PFS) and overall survival (OS) in first-line HER2-positive MBC (2,3)
Increases pathological complete response when combined with Trastuzumab and chemotherapy in the neoadjuvant setting (4)
Improves invasive disease-free survival (IDFS) in high-risk HER2-positive early breast cancer, particularly in patients with node-positive disease (5)
Key clinical trials
CLEOPATRA
In this randomized Phase 3 trial involving 808 patients, investigators evaluated Pertuzumab plus Trastuzumab and Docetaxel versus placebo plus Trastuzumab and docetaxel as first-line treatment for HER2-positive metastatic breast cancer. The primary endpoint was independently assessed PFS. Median PFS was 18.5 months versus 12.4 months with placebo (HR 0.62; 95% CI 0.51–0.75; P<0.001). With longer follow-up, median overall survival was 56.5 versus 40.8 months (HR 0.68; 95% CI 0.56–0.84; P<0.001), representing a 15.7-month improvement. The benefit was maintained with long-term follow-up, with median overall survival of 57.1 versus 40.8 months in the final analysis (2,3).
NeoSphere
In this randomized phase 2 trial, 417 patients with operable, locally advanced, or inflammatory HER2-positive breast cancer received one of four neoadjuvant regimens. The combination of Pertuzumab, Trastuzumab, and Docetaxel produced a significantly higher pathologic complete response rate than Trastuzumab plus docetaxel (45.8% vs. 29.0%; difference 16.8 percentage points; P=0.0141) (4).
APHINITY
In this randomized phase 3 trial, 4,805 patients with HER2-positive early breast cancer were randomized to Pertuzumab or placebo alongside standard chemotherapy and Trastuzumab. Invasive disease-free survival events occurred in 7.1% vs. 8.7% of patients (HR 0.81; 95% CI 0.66–1.00; P=0.045), with greater benefit in node-positive patients (3-year IDFS: 92.0% vs. 90.2%; HR 0.77; 95% CI 0.62–0.96; P=0.02) (5).
Common Adverse Events
Diarrhea (1)
Alopecia (1)
Nausea (1)
Fatigue (1)
Rash (1)
Vomiting (1)
Contraindications/Precautions
Left ventricular dysfunction and heart failure (1)
Embryo-fetal toxicity (1)
Verify pregnancy status before initiating treatment in females of reproductive potential (1)
Infusion-related and hypersensitivity reactions, including anaphylaxis (1)
Monitor patients for diarrhea (1)
Special notes for the clinician
Confirm HER2 status before initiating Pertuzumab (1)
Pertuzumab should be given in combination with Trastuzumab and chemotherapy, rather than as monotherapy (1)
Monitor cardiac function before and during the treatment (1)
Advise patients of the potential risk of embryo-fetal toxicity (1)
Abbreviations
ADCC: antibody-dependent cellular cytotoxicity; CI: confidence interval; EBC: early breast cancer; HER2: human epidermal growth factor receptor 2; HR: hazard ratio; IDFC: invasive disease-free survival; LVEF: left ventricular ejection fraction; MBC: metastatic breast cancer.
References
U.S. Food and Drug Administration. PERJETA® (pertuzumab) injection: US prescribing information. 2025. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125409s139lbl.pdf?utm_source
Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-119.
Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724-734.
Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere). Lancet Oncol. 2012;13(1):25-32.
von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122-131.
About the Author
Ramesh Mylapilli is the Founder & Managing Director of Crixus Health, with over 23 years of expertise in medical communications. Beginning as a medical writer, he has evolved into a seasoned leader across India and the Asia‑Pacific, consistently transforming complex science into clear, impactful communication for healthcare stakeholders. He is also the Founder of MedWriters, a platform that mentors and empowers aspiring medical writers through structured programs in medico‑marketing deliverables and scientific manuscripts. By combining writing excellence with leadership, Ramesh continues to champion innovation, education, and the advancement of medical communications.
Disclaimer
The content published on this platform has been developed by independent medical writers from diverse healthcare backgrounds, including members of the MedWriters Alumni Network. While every effort has been made to ensure accuracy, the authors, Rxnews team, partners, agents, and sponsors accept no responsibility for errors, omissions, or inaccuracies in this article, whether due to negligence or otherwise, nor for any consequences arising from its use. Inclusion or exclusion of any product does not imply endorsement or rejection by the publisher. For complaints or feedback, please write to contact@rxnews.in
Comments